Sugi Predict

Sugi Predict / Compounds / SCHEMBL5387584

SCHEMBL5387584

SCHEMBL5387584

COc1cc(CCl)ccc1OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.65
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ NPC1 O15118 3/20 0.59
▸ RAB9A P51151 3/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2D6 P10635 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ MTNR1A P48039 2/20 0.59
▸ MTNR1B P49286 2/20 0.59
▸ ABCB1 P08183 1/20 0.57
▸ ABCG2 Q9UNQ0 1/20 0.57
▸ BCHE P06276 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPT P10636 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6672350 0.94 TTR (0.60) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL11093699 0.92 TTR (0.59) TTRMEN1KMT2ANPC1RAB9A
Phosphine SCHEMBL4434544 0.92 TTR (0.59) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL25292206 0.92 TTR (0.56) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL29463780 0.92 TTR (0.56) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL2074825 0.90 SLC2A1 (0.52) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL25253735 0.86 TTR (0.52) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL29463715 0.86 TTR (0.52) TTRMEN1KMT2ANPC1RAB9A
SCHEMBL5653057 0.85 NPC1 (0.64) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL13917946 0.85 ABCB1 (0.62) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235719-A1 DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2025-11-13 — — WO disclosed
CN-103347859-B Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives EFFICIENT PHARMA MANAGEMENT CORP. (CN) 2015-12-02 — — CN disclosed
CN-103347859-A Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives EFFICIENT PHARMA MAN CORP 2013-10-09 — — CN disclosed
EP-2540695-A1 METHOD FOR PRODUCING HIGH PURITY AROMATIC METHYL ALCOHOL, AND HIGH PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT STORAGE STABILITY Ube Industries, Ltd. (JP) 2013-01-02 — — EP disclosed
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY UBE INDUSTRIES, LTD. (JP) 2012-12-20 — — US disclosed
US-8207340-B2 Imidazopyridinyl benzamide mitotic kinesin inhibitors CYTOKINETICS, INCORPORATED (US) 2012-06-26 — — US disclosed
US-8207340-B2 Imidazopyridinyl benzamide mitotic kinesin inhibitors CYTOKINETICS, INCORPORATED (US) 2012-06-26 — — US disclosed
US-20090312365-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2009-12-17 — — US disclosed
US-20090312365-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2009-12-17 — — US disclosed
US-7179823-B1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-20 — — US disclosed
US-20040152714-A1 Benzylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-05 — — US disclosed
EP-1228067-B1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-07-14 — — EP disclosed
EP-1395594-A1 NEW BENZYLAMINOPYRIMIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2004-03-10 — — EP disclosed
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists PHARMACIA CORPORATION 2004-03-04 — — US disclosed
EP-1313705-A1 GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS Pharmacia Corporation (US) 2003-05-28 — — EP disclosed
US-6531494-B1 Gem-substituted αvβ3 antagonists PHARMACIA CORPORATION 2003-03-11 — — US disclosed
WO-2002094832-A1 NEW BENZYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 — — WO disclosed
EP-1228067-A1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2002-08-07 — — EP disclosed
WO-2002018340-A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS PHARMACIA CORPORATION (US) 2002-03-07 — — WO disclosed
WO-2001038325-A1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists CACNG5, ITGAV, ITGA5 TTR 2317/4885MEN1 1452/4885KMT2A 3026/4885
US-20040152714-A1 Benzylaminopyrimidines DPYD, PGLS, TPMT TTR 2305/4885MEN1 2577/4885KMT2A 693/4885
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY ALKBH5, ALKBH2, ALKBH3 TTR 1712/4885MEN1 3064/4885KMT2A 75/4885
US-20090312365-A1 Certain Chemical Entities, Compositions, and Methods KIF5B, KIF2C, PLK1 TTR 4524/4885MEN1 1302/4885KMT2A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.